This inventor holds 2 USPTO granted patents and 6 published patent applications. Top assignee: University of Utah Research Foundation. Active years: 2020-2026.
Company Filing History:
Years Active: 2020-2026
Title: Hamid Ghandehari: Innovator in Chemoembolic Agents
Introduction
Hamid Ghandehari is a notable inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of cancer treatment through his innovative work on chemoembolic agents. His research focuses on enhancing the delivery of anti-cancer agents, which has the potential to improve patient outcomes.
Latest Patents
Hamid Ghandehari holds a patent for "Methods for producing chemoembolic agents for the delivery of anti-cancer agents." This patent describes chemoembolic compositions that include one or more anti-cancer agents and a silk-elastinlike protein polymer. The compositions are in liquid form prior to administration but convert to hydrogels upon administration to a subject. The administration of these compositions to tumors can reduce blood flow to the tumor and provide localized, sustained release of the anti-cancer agent, thereby minimizing systemic effects and toxicity.
Career Highlights
Hamid Ghandehari is affiliated with the University of Utah Research Foundation, where he continues to advance his research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that address critical challenges in cancer treatment.
Collaborations
Some of his notable coworkers include Joseph Cappello and Azadeh Poursaid, who contribute to the collaborative efforts in his research endeavors.
Conclusion
Hamid Ghandehari's innovative work in the development of chemoembolic agents represents a significant advancement in cancer treatment. His contributions have the potential to change the landscape of how anti-cancer therapies are delivered, ultimately benefiting patients in their fight against cancer.